HRP20120331T1 - Postupak sprječavanja ili liječenja infekcije bakterijom m. tuberculosis - Google Patents

Postupak sprječavanja ili liječenja infekcije bakterijom m. tuberculosis Download PDF

Info

Publication number: HRP20120331T1
Authority: HR; Croatia
Prior art keywords: pharmaceutical preparation; preparation according; seq; fusion protein; mammal
Prior art date: 2005-04-29

Application number

HRP20120331TT

Other languages

English (en)

Croatian (hr)

Inventor

Coler Rhea

Lobet Yves

Reed Steven

Original Assignee

Glaxosmithkline Biologicals Sa

Infectious Disease Research Institute (Idri)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-29

Filing date

2006-04-27

Publication date

2012-05-31

2006-04-27 Application filed by Glaxosmithkline Biologicals Sa, Infectious Disease Research Institute (Idri) filed Critical Glaxosmithkline Biologicals Sa

2012-05-31 Publication of HRP20120331T1 publication Critical patent/HRP20120331T1/hr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Mycology (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

HRP20120331TT 2005-04-29 2006-04-27 Postupak sprječavanja ili liječenja infekcije bakterijom m. tuberculosis HRP20120331T1 (hr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US67654905P	2005-04-29	2005-04-29
US77701706P	2006-02-27	2006-02-27
PCT/EP2006/004319 WO2006117240A2 (en)	2005-04-29	2006-04-27	Novel method for preventing or treating m tuberculosis infection

Publications (1)

Publication Number	Publication Date
HRP20120331T1 true HRP20120331T1 (hr)	2012-05-31

Family

ID=36972897

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
HRP20120331TT HRP20120331T1 (hr)	2005-04-29	2006-04-27	Postupak sprječavanja ili liječenja infekcije bakterijom m. tuberculosis
HRP20141125TT HRP20141125T1 (hr)	2005-04-29	2014-11-19	Postupak sprjeäśavanja ili lijeäśenja infekcije bakterijom m. tuberculosis
HRP20141184TT HRP20141184T1 (en)	2005-04-29	2014-12-08	Novel method for preventing or treating m. tuberculosis infection

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
HRP20141125TT HRP20141125T1 (hr)	2005-04-29	2014-11-19	Postupak sprjeäśavanja ili lijeäśenja infekcije bakterijom m. tuberculosis
HRP20141184TT HRP20141184T1 (en)	2005-04-29	2014-12-08	Novel method for preventing or treating m. tuberculosis infection

Country Status (24)

Country	Link
US (6)	US8470338B2 (sl)
EP (3)	EP2426141B1 (sl)
JP (4)	JP5164830B2 (sl)
KR (4)	KR101352806B1 (sl)
CN (3)	CN101273055B (sl)
AT (1)	ATE543832T1 (sl)
AU (1)	AU2006243357B2 (sl)
BR (1)	BRPI0611347A2 (sl)
CA (2)	CA2607715C (sl)
CY (1)	CY1112851T1 (sl)
DK (3)	DK2426141T3 (sl)
EA (1)	EA012576B1 (sl)
ES (3)	ES2381492T3 (sl)
HR (3)	HRP20120331T1 (sl)
IL (2)	IL186654A (sl)
MA (1)	MA29678B1 (sl)
NO (3)	NO340766B1 (sl)
NZ (1)	NZ562729A (sl)
PH (1)	PH12013502449A1 (sl)
PL (3)	PL2457926T3 (sl)
PT (3)	PT2426141E (sl)
SI (3)	SI2457926T1 (sl)
WO (1)	WO2006117240A2 (sl)
ZA (1)	ZA200709209B (sl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2426141T3 (da) *	2005-04-29	2014-11-10	Glaxosmithkline Biolog Sa	Fremgangsmåde til forebyggelse eller behandling af M tuberkuloseinfektioner
TWI457133B (zh)	2005-12-13	2014-10-21	Glaxosmithkline Biolog Sa	新穎組合物
BRPI0708865A8 (pt) *	2006-03-14	2019-01-22	Univ Oregon Health & Science	métodos para produzir uma resposta imune à tuberculose
EA021391B1 (ru)	2007-03-02	2015-06-30	Глаксосмитклайн Байолоджикалс С.А.	Способ индукции иммунного ответа, вакцинная композиция, ее применение и набор
US9717788B2 (en)	2007-03-02	2017-08-01	Glaxosmithkline Biologicals Sa	Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
WO2009025820A2 (en) *	2007-08-21	2009-02-26	Stc. Unm	Rationally improved isoniazid and ethionamide derivatives and activity through selective isotopic substitution
WO2009158284A2 (en) *	2008-06-26	2009-12-30	Mayo Foundation For Medical Education And Research	Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance
PL2315773T3 (pl)	2008-07-25	2017-07-31	Glaxosmithkline Biologicals S.A.	Polipeptydy, polinukleotydy i kompozycje do stosowania w leczeniu utajonej gruźlicy
ES2647321T3 (es) *	2008-07-25	2017-12-20	Glaxosmithkline Biologicals S.A.	Composiciones y procedimientos novedosos
BRPI0916704A2 (pt)	2008-07-25	2020-08-18	Glaxosmithkline Biologicals S.A.	composições farmacêutica, e imunogênica, usos de um polipeptídeo, e de um polinucleotídeo, proteína de fusão, e, polinucleotídeo
GB0815872D0 (en)	2008-09-01	2008-10-08	Pasteur Institut	Novel method and compositions
US9074001B2 (en)	2009-04-24	2015-07-07	Statens Serum Institut	Tuberculosis TB vaccine to prevent reactivation
MY156697A (en)	2010-01-27	2016-03-15	Glaxosmithkline Biolog Sa	Modified tuberculosis antigens
UA110118C2 (uk)	2010-12-14	2015-11-25	Ґлаксосмітклайн Байолоджікалз С.А.	Мікобактеріальна антигенна композиція
GB201022007D0 (en)	2010-12-24	2011-02-02	Imp Innovations Ltd	DNA-sensor
PL2661253T3 (pl) *	2011-01-04	2017-08-31	Archivel Farma, Sl	Preparat liposomowy odpowiedni do leczenia lub zapobiegania gruźlicy
GB201116248D0 (en)	2011-09-20	2011-11-02	Glaxosmithkline Biolog Sa	Liposome production using isopropanol
WO2013090897A1 (en) *	2011-12-15	2013-06-20	The Trustees Of The University Of Pennsylvania	Using adaptive immunity to detect drug resistance
US9682042B2 (en)	2012-01-12	2017-06-20	Archivel Farma, S.L.	MTB-C vaccine against asthma
BR112015002483A2 (pt)	2012-08-03	2017-11-07	Infectious Disease Res Inst	composições e métodos para o tratamento de uma infecção ativa por mycobacterium tuberculosis
WO2014047848A1 (en) *	2012-09-27	2014-04-03	Chengdu Yongan Pharmaceutical Co., Ltd.	Modified bcg strains with reduced or eliminated activity of lsr2 and pharmaceutical composition comprising same
CN102994595B (zh) *	2012-11-30	2018-10-26	广州白云山拜迪生物医药有限公司	一种融合蛋白包涵体的制备方法
CN102993266B (zh) *	2012-11-30	2019-08-23	广州白云山拜迪生物医药有限公司	一种融合蛋白的纯化和复性方法
GB201405921D0 (en) *	2014-04-02	2014-05-14	Glaxosmithkline Biolog Sa	Novel methods for inducing an immune response
US10588980B2 (en)	2014-06-23	2020-03-17	Novartis Ag	Fatty acids and their use in conjugation to biomolecules
US10335374B2 (en)	2014-12-04	2019-07-02	University System of Georgia, Valdosta State University	Tablet composition for anti-tuberculosis antibiotics
WO2016161386A1 (en) *	2015-04-02	2016-10-06	Biodesy, Inc.	Methods for determining protein structure using a surface-selective nonlinear optical technique
US10653679B2 (en)	2015-05-04	2020-05-19	Board Of Trustees Of Michigan State University	Compositions and methods for inhibiting bacterial growth
GB201513176D0 (en) *	2015-07-27	2015-09-09	Glaxosmithkline Biolog Sa	Novel methods for inducing an immune response
JP7136777B2 (ja)	2016-12-07	2022-09-13	グラクソスミスクラインバイオロジカルズソシエテアノニム	新規プロセス
WO2019178472A1 (en) *	2018-03-16	2019-09-19	Washington University In St. Louis	Use of fatty acid oxidation inhibitors as antimicrobials
US11717519B2 (en)	2017-04-21	2023-08-08	Washington University In St. Louis	Use of fatty acid oxidation inhibitors as antimicrobials
GB201707700D0 (en)	2017-05-12	2017-06-28	Glaxosmithkline Biologicals Sa	Dried composition
WO2022119899A1 (en) *	2020-12-02	2022-06-09	Shionogi & Co., Ltd.	A medicament for treating mycobacterial infection characterized by combining a cytochrome bc1 inhibitor with clarithromycin or azithromycin
WO2023034783A1 (en)	2021-08-31	2023-03-09	Vir Biotechnology, Inc.	Tuberculosis vaccines
KR102534846B1 (ko)	2021-12-14	2023-05-19	재단법인 환동해산업연구원	결핵균에 항균 활성을 가지는 해조류 추출물
CN116162141B (zh) *	2022-11-30	2024-04-12	中国疾病预防控制中心传染病预防控制所	一种结核分枝杆菌抗原epcra013及其应用

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4235877A (en)	1979-06-27	1980-11-25	Merck & Co., Inc.	Liposome particle containing viral or bacterial antigenic subunit
US4769330A (en)	1981-12-24	1988-09-06	Health Research, Incorporated	Modified vaccinia virus and methods for making and using the same
US4603112A (en)	1981-12-24	1986-07-29	Health Research, Incorporated	Modified vaccinia virus
US4436727A (en)	1982-05-26	1984-03-13	Ribi Immunochem Research, Inc.	Refined detoxified endotoxin product
US4866034A (en)	1982-05-26	1989-09-12	Ribi Immunochem Research Inc.	Refined detoxified endotoxin
US4751180A (en)	1985-03-28	1988-06-14	Chiron Corporation	Expression using fused genes providing for protein product
GB8508845D0 (en)	1985-04-04	1985-05-09	Hoffmann La Roche	Vaccinia dna
US4777127A (en)	1985-09-30	1988-10-11	Labsystems Oy	Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en)	1985-12-02	1990-06-19	G. D. Searle And Company	Covalently linked polypeptide cell modulators
US4877611A (en)	1986-04-15	1989-10-31	Ribi Immunochem Research Inc.	Vaccine containing tumor antigens and adjuvants
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US6024983A (en)	1986-10-24	2000-02-15	Southern Research Institute	Composition for delivering bioactive agents for immune response and its preparation
US5075109A (en)	1986-10-24	1991-12-24	Southern Research Institute	Method of potentiating an immune response
GB8702816D0 (en)	1987-02-07	1987-03-11	Al Sumidaie A M K	Obtaining retrovirus-containing fraction
CA1340522C (en) *	1987-03-10	1999-05-04	Heinz Dobeli	Fusion proteins containing neighbouring histidines for improved purification
US5057540A (en)	1987-05-29	1991-10-15	Cambridge Biotech Corporation	Saponin adjuvant
CA1331443C (en)	1987-05-29	1994-08-16	Charlotte A. Kensil	Saponin adjuvant
US4897268A (en)	1987-08-03	1990-01-30	Southern Research Institute	Drug delivery system and method of making the same
WO1989001973A2 (en)	1987-09-02	1989-03-09	Applied Biotechnology, Inc.	Recombinant pox virus for immunization against tumor-associated antigens
JPH04505547A (ja)	1988-01-04	1992-10-01	イー・アイ・デユポン・ド・ネモアース・アンド・コンパニー	細胞混合物から特定の細胞を単離するための多段アフィニティー法
US5215926A (en)	1988-06-03	1993-06-01	Cellpro, Inc.	Procedure for designing efficient affinity cell separation processes
AP129A (en)	1988-06-03	1991-04-17	Smithkline Biologicals S A	Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en)	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
US5549910A (en)	1989-03-31	1996-08-27	The Regents Of The University Of California	Preparation of liposome and lipid complex compositions
EP0487587A1 (en)	1989-08-18	1992-06-03	Chiron Corporation	Recombinant retroviruses delivering vector constructs to target cells
US5725871A (en)	1989-08-18	1998-03-10	Danbiosyst Uk Limited	Drug delivery compositions comprising lysophosphoglycerolipid
KR920007887B1 (ko)	1989-08-29	1992-09-18	스즈키 지도오샤 고오교오 가부시키가이샤	내연기관의 배기가스 정화장치
US5707644A (en)	1989-11-04	1998-01-13	Danbiosyst Uk Limited	Small particle compositions for intranasal drug delivery
US5466468A (en)	1990-04-03	1995-11-14	Ciba-Geigy Corporation	Parenterally administrable liposome formulation comprising synthetic lipids
WO1991016116A1 (en)	1990-04-23	1991-10-31	Cellpro Incorporated	Immunoselection device and method
SE466259B (sv)	1990-05-31	1992-01-20	Arne Forsgren	Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
JP3218637B2 (ja)	1990-07-26	2001-10-15	大正製薬株式会社	安定なリポソーム水懸濁液
EP0468520A3 (en)	1990-07-27	1992-07-01	Mitsui Toatsu Chemicals, Inc.	Immunostimulatory remedies containing palindromic dna sequences
JP2958076B2 (ja)	1990-08-27	1999-10-06	株式会社ビタミン研究所	遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
DK0553288T3 (da)	1990-10-18	1997-12-29	Cellpro Inc	Apparat og fremgangsmåde til udskillelse af partikler ved brug af en eftergivende beholder
US5399363A (en)	1991-01-25	1995-03-21	Eastman Kodak Company	Surface modified anticancer nanoparticles
US5145684A (en)	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
EP0878545A3 (en)	1991-08-15	1998-12-16	SMITHKLINE BEECHAM BIOLOGICALS s.a.	OSP a protein of borrelia burgdorferi subgroups, encoding genes and vaccines
US5240856A (en)	1991-10-23	1993-08-31	Cellpro Incorporated	Apparatus for cell separation
US5756353A (en)	1991-12-17	1998-05-26	The Regents Of The University Of California	Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ES2105262T3 (es)	1992-05-18	1997-10-16	Minnesota Mining & Mfg	Dispositivo de suministro de farmaco a traves de las mucosas.
US5792451A (en)	1994-03-02	1998-08-11	Emisphere Technologies, Inc.	Oral drug delivery compositions and methods
PT761231E (pt)	1992-06-25	2000-06-30	Smithkline Beecham Biolog	Composicao de vacina contendo adjuvantes
DK0678034T3 (da)	1993-01-11	1999-11-08	Dana Farber Cancer Inst Inc	Induktion af cytotoksiske T-lymfocytreaktioner
FR2702160B1 (fr)	1993-03-02	1995-06-02	Biovecteurs As	Vecteurs particulaires synthétiques et procédé de préparation.
US5776468A (en)	1993-03-23	1998-07-07	Smithkline Beecham Biologicals (S.A.)	Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
FR2704145B1 (fr)	1993-04-21	1995-07-21	Pasteur Institut	Vecteur particulaire et composition pharmaceutique le contenant.
US5955077A (en)	1993-07-02	1999-09-21	Statens Seruminstitut	Tuberculosis vaccine
US5543158A (en)	1993-07-23	1996-08-06	Massachusetts Institute Of Technology	Biodegradable injectable nanoparticles
GB9326253D0 (en)	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
US5741516A (en)	1994-06-20	1998-04-21	Inex Pharmaceuticals Corporation	Sphingosomes for enhanced drug delivery
US5551622A (en)	1994-07-13	1996-09-03	Yoon; Inbae	Surgical stapler
CA2560114A1 (en)	1994-07-15	1996-02-01	The University Of Iowa Research Foundation	Immunomodulatory oligonucleotides
FR2723849B1 (fr)	1994-08-31	1997-04-11	Biovector Therapeutics Sa	Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
AUPM873294A0 (en)	1994-10-12	1994-11-03	Csl Limited	Saponin preparations and use thereof in iscoms
US5795587A (en)	1995-01-23	1998-08-18	University Of Pittsburgh	Stable lipid-comprising drug delivery complexes and methods for their production
US5580579A (en)	1995-02-15	1996-12-03	Nano Systems L.L.C.	Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en)	1995-04-04	1998-07-29	Elan Corp Plc	Controlled release biodegradable nanoparticles containing insulin
UA56132C2 (uk)	1995-04-25	2003-05-15	Смітклайн Бічем Байолоджікалс С.А.	Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
WO1996038591A1 (en)	1995-06-02	1996-12-05	Incyte Pharmaceuticals, Inc.	IMPROVED METHOD FOR OBTAINING FULL-LENGTH cDNA SEQUENCES
US5738868A (en)	1995-07-18	1998-04-14	Lipogenics Ltd.	Liposome compositions and kits therefor
DK2154248T3 (da)	1995-09-01	2012-01-30	Corixa Corp	Forbindelser og fremgangsmåder til diagnose af tuberkulose
CZ300953B6 (cs)	1995-09-01	2009-09-23	Corixa Corporation	Polypeptid, farmaceutický prostredek a vakcína s jeho obsahem, zpusob prípravy a použití polypeptidu, DNA molekula a její použití, expresní vektor, hostitelská bunka, fúsní protein a diagnostický kit
US6290969B1 (en)	1995-09-01	2001-09-18	Corixa Corporation	Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO1997024447A1 (en)	1996-01-02	1997-07-10	Chiron Corporation	Immunostimulation mediated by gene-modified dendritic cells
US5856462A (en)	1996-09-10	1999-01-05	Hybridon Incorporated	Oligonucleotides having modified CpG dinucleosides
JP4111403B2 (ja)	1996-10-11	2008-07-02	ザリージェンツオブザユニバーシティーオブカリフォルニア	免疫刺激ポリヌクレオチド／免疫調節分子複合体
CA2268036A1 (en)	1996-10-11	1998-04-23	Corixa Corporation	Compounds and methods for diagnosis of tuberculosis
US5655998A (en)	1996-12-03	1997-08-12	Yu; Chih-An	Space walking exerciser
BR9811262A (pt)	1997-04-01	2000-10-17	Ribi Immunochem Research Inc	Composições auxiliares imunológicas aquosas de lipìdio de monofosforila a.
GB9727262D0 (en)	1997-12-24	1998-02-25	Smithkline Beecham Biolog	Vaccine
EP1584685B1 (en)	1998-02-05	2011-04-13	GlaxoSmithKline Biologicals SA	Tumor-associated antigen derivatives from the mage family, used for the preparation of fusion proteins with T-helper epitopes and of compositions for vaccination
CZ302870B6 (cs)	1998-04-07	2011-12-28	Corixa Corporation	Polynukleotid, polypeptid, farmaceutický prostredek, vakcínový prostredek a jejich použití k lécbe a prevenci infekce tuberkulózou
WO2001024820A1 (en)	1999-10-07	2001-04-12	Corixa Corporation	Fusion proteins of mycobacterium tuberculosis
US7472098B2 (en)	2000-02-14	2008-12-30	Ubs Financial Services, Inc.	System and method for execution of trades made pursuant to stock option and purchase plans
EP1542732B1 (en) *	2000-06-20	2009-09-16	Corixa Corporation	Fusion proteins of mycobacterium tuberculosis
US20030143240A1 (en)	2000-06-27	2003-07-31	Cabezon-Silva Teresa Elisa Virginia	Prostase protein vaccine comprising derivatised thiol residues and methods for producing said antigen
US20030175294A1 (en) *	2001-03-13	2003-09-18	Corixa Corporation	Heterologous fusion protein constructs comprising a Leishmania antigen
CN101570594B (zh)	2002-02-14	2012-06-20	三井化学株式会社	聚酯树脂及聚酯制备用催化剂、用此催化剂制备聚酯树脂的方法
WO2003070187A2 (en) *	2002-02-15	2003-08-28	Corixa Corporation	Fusion proteins of mycobacterium tuberculosis
GB0411411D0 (en)	2004-05-21	2004-06-23	Glaxosmithkline Biolog Sa	Vaccines
US7301098B2 (en)	2005-01-19	2007-11-27	Panduit Corp.	Communication channels with suppression cores
DK2426141T3 (da) *	2005-04-29	2014-11-10	Glaxosmithkline Biolog Sa	Fremgangsmåde til forebyggelse eller behandling af M tuberkuloseinfektioner
JP4468858B2 (ja)	2005-06-01	2010-05-26	オリンパスイメージング株式会社	データ符号化装置、データ符号化方法、プログラム
US7296798B2 (en)	2006-01-31	2007-11-20	Matt Overfield	Gameboard, games played on board and methods of play requiring strategy and luck
US9074001B2 (en) *	2009-04-24	2015-07-07	Statens Serum Institut	Tuberculosis TB vaccine to prevent reactivation
CN102549336B (zh)	2009-07-21	2014-11-26	库柏技术公司	将发光二极管(led)模块连接于散热器组件、反光件以及电路
UA110118C2 (uk)	2010-12-14	2015-11-25	Ґлаксосмітклайн Байолоджікалз С.А.	Мікобактеріальна антигенна композиція
US9119754B2 (en)	2011-10-08	2015-09-01	Michael Dennis	Mattress overlay system with positionally adjustable, lateral ramp-wedge bolster structure
US9051890B2 (en)	2013-10-28	2015-06-09	Ford Global Technologies, Llc	Method for estimating charge air cooler condensation storage with an intake oxygen sensor
US9903268B2 (en)	2015-04-02	2018-02-27	Ford Global Technologies, Llc	Internal combustion engine with two-stage supercharging capability and with exhaust-gas aftertreatment arrangement, and method for operating an internal combustion engine
US9810514B2 (en)	2015-09-08	2017-11-07	Deufol Sunman Inc.	Ammunition carrier consumer package

2006
- 2006-04-27 DK DK11190079.1T patent/DK2426141T3/da active
- 2006-04-27 HR HRP20120331TT patent/HRP20120331T1/hr unknown
- 2006-04-27 CN CN200680023551.3A patent/CN101273055B/zh not_active Expired - Fee Related
- 2006-04-27 EP EP11190079.1A patent/EP2426141B1/en active Active
- 2006-04-27 SI SI200631870T patent/SI2457926T1/sl unknown
- 2006-04-27 EP EP11190080.9A patent/EP2457926B1/en active Active
- 2006-04-27 AT AT06753523T patent/ATE543832T1/de active
- 2006-04-27 CN CN201610085598.8A patent/CN106390108B/zh not_active Expired - Fee Related
- 2006-04-27 CN CN2011102974226A patent/CN102617739A/zh active Pending
- 2006-04-27 JP JP2008508169A patent/JP5164830B2/ja not_active Expired - Fee Related
- 2006-04-27 CA CA2607715A patent/CA2607715C/en not_active Expired - Fee Related
- 2006-04-27 AU AU2006243357A patent/AU2006243357B2/en not_active Ceased
- 2006-04-27 PT PT111900791T patent/PT2426141E/pt unknown
- 2006-04-27 PT PT111900809T patent/PT2457926E/pt unknown
- 2006-04-27 PL PL11190080T patent/PL2457926T3/pl unknown
- 2006-04-27 BR BRPI0611347-8A patent/BRPI0611347A2/pt active Search and Examination
- 2006-04-27 CA CA2821389A patent/CA2821389C/en not_active Expired - Fee Related
- 2006-04-27 EP EP06753523A patent/EP1877426B1/en active Active
- 2006-04-27 WO PCT/EP2006/004319 patent/WO2006117240A2/en active Application Filing
- 2006-04-27 ES ES06753523T patent/ES2381492T3/es active Active
- 2006-04-27 PT PT06753523T patent/PT1877426E/pt unknown
- 2006-04-27 KR KR1020077027885A patent/KR101352806B1/ko not_active Expired - Fee Related
- 2006-04-27 ES ES11190080.9T patent/ES2524572T3/es active Active
- 2006-04-27 NZ NZ562729A patent/NZ562729A/en not_active IP Right Cessation
- 2006-04-27 KR KR20157004060A patent/KR20150036658A/ko not_active Ceased
- 2006-04-27 KR KR1020137024859A patent/KR20130110233A/ko not_active Ceased
- 2006-04-27 ES ES11190079.1T patent/ES2524570T3/es active Active
- 2006-04-27 SI SI200631315T patent/SI1877426T1/sl unknown
- 2006-04-27 DK DK11190080.9T patent/DK2457926T3/da active
- 2006-04-27 US US11/912,730 patent/US8470338B2/en not_active Expired - Fee Related
- 2006-04-27 PL PL11190079T patent/PL2426141T3/pl unknown
- 2006-04-27 EA EA200702081A patent/EA012576B1/ru not_active IP Right Cessation
- 2006-04-27 PL PL06753523T patent/PL1877426T3/pl unknown
- 2006-04-27 DK DK06753523.7T patent/DK1877426T3/da active
- 2006-04-27 SI SI200631856T patent/SI2426141T1/sl unknown
- 2006-04-27 KR KR1020127008426A patent/KR20120089475A/ko not_active Ceased
2007
- 2007-10-11 NO NO20075201A patent/NO340766B1/no not_active IP Right Cessation
- 2007-10-15 IL IL186654A patent/IL186654A/en not_active IP Right Cessation
- 2007-10-25 MA MA30313A patent/MA29678B1/fr unknown
- 2007-10-25 ZA ZA2007/09209A patent/ZA200709209B/en unknown
2011
- 2011-09-13 IL IL215112A patent/IL215112A/en not_active IP Right Cessation
- 2011-09-22 JP JP2011207361A patent/JP2012065650A/ja active Pending
2012
- 2012-03-28 NO NO20120381A patent/NO340206B1/no not_active IP Right Cessation
- 2012-04-24 CY CY20121100382T patent/CY1112851T1/el unknown
- 2012-10-12 JP JP2012227192A patent/JP5659207B2/ja not_active Expired - Fee Related
2013
- 2013-05-16 US US13/895,574 patent/US9056913B2/en not_active Expired - Fee Related
- 2013-11-26 PH PH12013502449A patent/PH12013502449A1/en unknown
2014
- 2014-09-24 NO NO20141158A patent/NO345071B1/no not_active IP Right Cessation
- 2014-10-24 JP JP2014217282A patent/JP2015057403A/ja active Pending
- 2014-11-19 HR HRP20141125TT patent/HRP20141125T1/hr unknown
- 2014-12-08 HR HRP20141184TT patent/HRP20141184T1/hr unknown
2015
- 2015-01-23 US US14/603,935 patent/US9655958B2/en not_active Expired - Fee Related
2017
- 2017-03-20 US US15/463,557 patent/US10105430B2/en not_active Expired - Fee Related
2018
- 2018-09-19 US US16/135,553 patent/US10350283B2/en not_active Expired - Fee Related
2019
- 2019-06-25 US US16/451,040 patent/US10639361B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US8470338B2 (en)	2013-06-25
KR20120089475A (ko)	2012-08-10
US9056913B2 (en)	2015-06-16
AU2006243357B2 (en)	2012-03-15
ATE543832T1 (de)	2012-02-15
PT2426141E (pt)	2014-11-25
KR20130110233A (ko)	2013-10-08
ES2381492T3 (es)	2012-05-28
NZ562729A (en)	2009-10-30
DK2426141T3 (da)	2014-11-10
NO340206B1 (no)	2017-03-20
EP2426141A2 (en)	2012-03-07
MA29678B1 (fr)	2008-08-01
JP5164830B2 (ja)	2013-03-21
IL186654A (en)	2013-04-30
US10639361B2 (en)	2020-05-05
HRP20141125T1 (hr)	2015-01-02
NO20120381L (no)	2008-01-25
JP2012065650A (ja)	2012-04-05
CY1112851T1 (el)	2016-02-10
PL1877426T3 (pl)	2012-10-31
EP2457926B1 (en)	2014-09-24
EP1877426B1 (en)	2012-02-01
EP1877426A2 (en)	2008-01-16
DK2457926T3 (da)	2015-01-05
WO2006117240A3 (en)	2007-01-18
JP2008539187A (ja)	2008-11-13
IL215112A0 (en)	2011-10-31
CA2607715A1 (en)	2006-11-09
PT2457926E (pt)	2014-11-25
CN106390108A (zh)	2017-02-15
HRP20141184T1 (en)	2015-03-13
CN101273055B (zh)	2016-03-16
CN101273055A (zh)	2008-09-24
CN106390108B (zh)	2020-09-08
US20090123491A1 (en)	2009-05-14
SI1877426T1 (sl)	2012-06-29
KR101352806B1 (ko)	2014-02-17
NO340766B1 (no)	2017-06-19
EP2426141A3 (en)	2012-08-15
EA012576B1 (ru)	2009-10-30
WO2006117240A2 (en)	2006-11-09
DK1877426T3 (da)	2012-05-14
AU2006243357A1 (en)	2006-11-09
ES2524572T3 (es)	2014-12-10
US20140050776A1 (en)	2014-02-20
KR20080021624A (ko)	2008-03-07
NO20075201L (no)	2008-01-25
CN102617739A (zh)	2012-08-01
CA2607715C (en)	2015-11-24
ZA200709209B (en)	2009-12-30
IL215112A (en)	2013-07-31
PT1877426E (pt)	2012-05-02
ES2524570T3 (es)	2014-12-10
US20170196961A1 (en)	2017-07-13
EP2457926A1 (en)	2012-05-30
PH12013502449A1 (en)	2015-12-14
PL2457926T3 (pl)	2015-03-31
SI2457926T1 (sl)	2015-01-30
NO20141158L (no)	2008-01-25
US20150231224A1 (en)	2015-08-20
JP2015057403A (ja)	2015-03-26
KR20150036658A (ko)	2015-04-07
EP2426141B1 (en)	2014-10-01
SI2426141T1 (sl)	2015-01-30
US10350283B2 (en)	2019-07-16
JP5659207B2 (ja)	2015-01-28
BRPI0611347A2 (pt)	2010-08-31
JP2013040190A (ja)	2013-02-28
CA2821389C (en)	2015-11-17
US20170065696A9 (en)	2017-03-09
US20190030154A1 (en)	2019-01-31
IL186654A0 (en)	2008-01-20
US9655958B2 (en)	2017-05-23
US10105430B2 (en)	2018-10-23
EA200702081A1 (ru)	2008-04-28
NO345071B1 (no)	2020-09-14
CA2821389A1 (en)	2006-11-09
PL2426141T3 (pl)	2015-02-27
US20190307872A1 (en)	2019-10-10

Publication	Publication Date	Title
HRP20120331T1 (hr)	2012-05-31	Postupak sprječavanja ili liječenja infekcije bakterijom m. tuberculosis
JP2008539187A5 (sl)	2009-06-18
Villena et al.	2018	Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines
JP6215260B2 (ja)	2017-10-18	再活性化を予防する結核ｔｂワクチン
DK2270173T3 (en)	2016-03-07	Neisserial combination compositions
Aagaard et al.	2009	TB vaccines: current status and future perspectives
Brazier et al.	2020	Towards new TB vaccines
JP2008543890A5 (sl)	2009-12-24
US10004793B2 (en)	2018-06-26	M.tuberculosis vaccines
Flach et al.	2011	A truncated form of HpaA is a promising antigen for use in a vaccine against Helicobacter pylori
Read	2019	Neisseria meningitidis and meningococcal disease: recent discoveries and innovations
Kuhdari et al.	2016	Meningococcal B vaccination: real-world experience and future perspectives
Osterloh	2020	The neglected challenge: Vaccination against rickettsiae
CN101745104A (zh)	2010-06-23	含有复合佐剂的结核亚单位疫苗
Reed et al.	2003	Vaccines for parasitic and bacterial diseases
Kaaijk et al.	2014	Routine vaccination against MenB: considerations for implementation
JP2009504149A5 (sl)	2009-08-27
CN103118702A (zh)	2013-05-22	活动性结核病的治疗性接种
Breiman et al.	1999	Vaccines to prevent respiratory infection: opportunities on the near and far horizon
CA2598078A1 (en)	2006-08-24	Compositions for eliciting an immune response against mycobacterium avium subspecies paratuberculosis
FR2809960B1 (fr)	2004-04-23	Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante
Hovav et al.	2006	Pseudo-rationale design of efficient TB vaccines: lesson from the mycobacterial 27-kDa lipoprotein
JP4433147B2 (ja)	2010-03-17	レプトスピラ病に対する感染防御活性を有する薬剤
Miyazaki et al.	1999	Host immune responses to ribosome, ribosomal proteins, and RNA from Mycobacterium bovis bacille de Calmette–Gúerin
Coyne-Beasley et al.	2021	01. Serum Bactericidal Activity Against Circulating and Reference Strains of Meningococcal Serogroup B in the United States: A Review of Meningococcal Serogroup B (MenB) Vaccines in Adolescents and Young Adults